ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates
PR Newswire•13/08/2026•07:30 ET
0
Whiz Insights
ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates
Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026
Get started
Create a free account to read the full story.